Satellos Receives Clearance by U.S. FDA and Global Regulators to Initiate Pediatric Phase 2 Study of SAT-3247 for Duchenne Muscular Dystrophy Nanotech Investing
Vaxcyte Doses First Participants in the OPUS Phase 3, Noninferiority Trial Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease and Pneumonia in Adults Nanotech Investing
Innovent Announces Inclusion of Seven Innovative Drugs including TYVYT New Indication and SYCUME in China's National Reimbursement Drug List Nanotech Investing
Nuvation Bio Announces Publication of Positive Phase 2 Study Results for Safusidenib for the Treatment of Grade 2 IDH1-Mutant Glioma in Neuro-Oncology Nanotech Investing
Universal Ibogaine advises further on application for Management Cease Trade Order Nanotech Investing
Soleno Therapeutics to Present at the Piper Sandler 37th Annual Healthcare Conference Nanotech Investing
GreenPort Exclusive Interview with dynaCERT: Hydrogen Emissions Savings on the Quayside Cleantech Investing
Satellos Announces Publication in Nature Communications Supporting its Novel Treatment Approach for Duchenne Muscular Dystrophy Nanotech Investing
